HOME ＞ 研究業績詳細
研究業績詳細
堀本 義哉（ホリモト ヨシヤ）
| 研究テーマ | 乳癌の浸潤機構、内分泌療法反応性 |
|---|---|
| 研究業績（論文） | R Semba, Y Horimoto, et al. Azithromycin induces read-through of the nonsense Apc allele and prevents intestinal tumorigenesis in C3B6F1 ApcMin/+ mice. Biomed Pharmacother 2023 (in press) M Yuan, H Saeki, Y Horimoto, et al. Stromal Ki67 expression might be a useful marker for distinguishing fibroadenoma from benign phyllodes tumor of the breast. Int J Surg Pathol 2023 R Semba, Y Horimoto, et al. Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancer. Sci Rep 13:5281, 2023 M Amano, Y Horimoto, et al. Feasibility of quantitative MRI using 3D-QALAS for discriminating immunohistochemical status in invasive ductal carcinoma of the breast. J Magn Reson Imaging, 2023 [Online ahead of print] H Onagi, Y Horimoto, et al. High platelet-to-lymphocyte ratios in triple negative breast cancer associates with immunosuppressive status of TILs. Breast Cancer Res 24:67, 2022 H Jimbo, Y Horimoto, et al. Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer. Breast Cancer Res Treat 196:291-298, 2022 MT Hlaing, Y Horimoto, et al. Tamoxifen-resistant breast cancer cells exhibit reactivity with Wisteria floribunda agglutinin. PLoS ONE 17:e0273513, 2022 A Tobe, Y Horimoto, et al. Impact of diabetes on patient outcomes in breast cancer patients. Breast Care 2022 M Nahla, Y Horimoto, et al. Characterization of the immune microenvironment in inflammatory breast cancer using multiplex immunofluorescence. Pathobiology 2022 Y Horimoto, et al. Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients. BMC Cancer 22:242, 2022 K Suzuki, Y Horimoto, et al. Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities. Cancer Sci 2022 (doi: 10.1111/cas.15309) M Morita, Y Horimoto, et al. Is adjuvant chemotherapy necessary in older patients with breast cancer? Breast Cancer 2022 A Shikanai, Y Horimoto, et al. Clinicopathological features related to the efficacy of CDK4/6 inhibitor-based treatments in metastatic breast cancer. Breast Cancer: Basic Clin Res 16:1-9, 2022 A Sakaguchi, Y Horimoto, et al. Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res 23:99, 2021 Y Ishizuka and Y Horimoto. Re: The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only: A Multi-Center, Prospective Registry Study. Ann Surg Oncol 28(Suppl3):784, 2021 Y Ishizuka, Y Horimoto, et al. Clinicopathological examination of metaplastic spindle cell carcinoma of the breast: case series. Breast Cancer Basic Clin Res 15:1-6, 2021 T Itoh, R Hatano, Y Horimoto, et al. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance through endoplasmic reticulum stress signaling pathway in triple negative breast cancer cells (TNBC). Cell Death Dis 12:520, 2021 M Sakata-Matsuzawa, K Denda-Nagai, H Fujihira, M Noji, K Ishii-Schrade, A Matsuda, A Kuno, M Okazaki, K Nakai, Y Horimoto, M Saito, T Irimura. Glycans unique to the relapse-prone subset within triple-negative breast cancer as revealed by lectin array-based analysis of surgical specimens. PLoS One 16: e0250747, 2021 R Sasaki, Y Horimoto, et al. Molecular characteristics of lymphocyte-predominant triple-negative breast cancer. Anticancer Res 41:2133-2140, 2021 M Okazaki, K Mogushi, K Denda-Nagai, H Fujihira, M Noji, K Ishii-Schrade, M Sakata-Matsuzawa, K Nakai, Y Horimoto, M Saito, T Irimura. Biological and clinicopathological implications of beta-3-N-acetylglucosaminyltransferase 8 in triple-negative breast cancer. Anticancer Res 41:845-858, 2021 M Nakamura, Y Ishizuka, Y Horimoto, et al. Clinicopathological features of breast cancer without mammographic findings suggesting malignancy. Breast 54:335-342, 2020 Y Horimoto, M Tanabe. Intrinsic subtype distribution should vary according to institutions. Breast 54:349, 2020 K Kuroda, Y Matsumura, Y Ikemoto, T Segawa, T Hashimoto, J Fukuda, K Nakagawa, T Uchida, A Ochiai, Y Horimoto, A Arakawa, S Nojiri, A Itakura, R Sugiyama. Analysis of the risk factors and treatment for repeated implantation failure: OPtimization of Thyroid function, IMmunity and Uterine Milieu (OPTIMUM) treatment strategy. Am J Reprod Immunol 85(5):e13376, 2021 F Murakami, Y Tsuboi, Y Takahashi, Y Horimoto, et al. Short somatic alterations at the site of copy number variation in breast cancer. Cancer Sci 112:444-453, 2021 S Sai, E Kim, G Vares, M Suzuki, D Yu, Y Horimoto, and M Hayashi. Combination of Carbon-ion Beam and Dual Tyrosine Kinase Inhibitor, Lapatinib, Effectively Destroys HER2 positive Breast Cancer Stem-like Cells. Am J Cancer Res 10:2371-2386, 2020 Y Yoshida-Ichikawa, Y Horimoto, et al. Ipsilateral breast tumor control following hypofractionated and conventional fractionated whole-breast irradiation for early breast cancer: A long term follow-up. Breast Cancer 28:92-98, 2021 Y Ishizuka, Y Horimoto, et al. Predictive factors for non-sentinel nodal metastasis in patients with sentinel lymph node-positive breast cancer. Anticancer Res 40:4405-4412, 2020 Horimoto Y, et al. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer. Cancer Sci 111:2647-2654, 2020 Horimoto Y et al. High FOXA1 protein expression might predict late recurrence in patients with estrogenpositive and HER2-negative breast cancer. Breast Cancer Res and Treat 183:41-48, 2020 Watanabe J, Saito M, Horimoto Y, et al. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: A single institutional experience. Breast Cancer Res Treat 181:211-220, 2020 Myojin M, Horimoto Y, et al. Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer. Breast Cancer 27:732-8, 2020 Hayward S, Horimoto Y, et al. The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer. J Pathol 251:63-73, 2020 Nogami N, Nakai K, Horimoto Y, et al. Factors affecting metastatic breast cancer patient decisions regarding terminal care locations. Am J Hospice Palliat Med 37:853-858, 2020 Ito M, Horimoto Y et al. Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer. Med Oncol 36:89, 2019 Saeki H, May T, Horimoto Y et al. Usefulness of immunohistochemistry for mismatch repair protein and microsatellite instability examination in adenocarcinoma and background endometrium of sporadic endometrial cancer cases. J Obstet Gynaecol Res 45:2037-42, 2019 Horimoto Y et al. Estrogen receptor-positive ductal carcinoma in situ frequently overexpresses HER2 protein without gene amplification. Am J Surg Pathol 43:1221-8, 2019 Nakai K, Horimoto Y et al. Pathological and radiological assessments of Paget’s disease. Ann Breast Surg 3:11, 2019 Miyoshi Y, Shien T, Horimoto Y et al. Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor‑positive/human epidermal growth factor receptor type 2 negative breast cancer. Oncol Lett 17:2177-86, 2019 Uomori T, Horimoto Y et al. Breast cancer in lean postmenopausal women might have specific pathological features. In Vivo 33:483-7, 2019 Horimoto Y et al. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin‑based treatment in 22 patients with metastatic breast cancer: a pilot study. J Transl Med 16:287, 2018 Horimoto Y et al. Elucidation of inhibitory effects on metastatic sentinel lymph nodes of breast cancer during One-Step Nucleic Acid Amplification. Sci Rep 8:7563, 2018 Okazaki M, Horimoto Y et al. Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2‑negative metastatic breast cancer. Med Oncol 35:48, 2018 Ogiya A, Yamazaki K, Horimoto Y et al. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Breast Cancer 24:473-482, 2017 Tokuda E, Horimoto Y et al. Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer. Hum Pathol 63:40-45, 2017 Uomori T, Horimoto Y et al. Relationship between alcohol metabolism and chemotherapy-induced emetic events in breast cancer patients. Breast Cancer 702-7,2017 Igari F, Sato E, Horimoto Y et al. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma. Hum Pathol 70:129-138, 2017 Tanabe M, Fujiyama S, Horimoto Y. Developmentally regulated GTP binding protein 2 (DRG2) and Nup107 are associated with epigenetic regulation via H2A.Z on promoter regions of specific genes in MCF7 breast cancer cells. J Clin Epigenet 2:4, 2016 Horimoto Y, Hayashi T, Arakawa A. Pathology of healing: what else might we look at? Cancer Med 2016 Oct 26. doi: 10.1002/cam4.952. Horimoto Y et al. Combination of cancer stem cell markers CD44 and CD24 is superior to ALDH1 as a prognostic indicator in breast cancer patients with distant metastases. PLoS ONE 11: e0165253, 2016 Miyoshi Y, Horimoto Y et al. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence. Breast Cancer Res 18:73, 2016 Himuro T, Horimoto Y et al. Activated caspase 3 expression in remnant disease after neo-adjuvant chemotherapy may predict outcomes of breast cancer patients. Ann Surg Oncol 23:2235-41, 2016 Himuro T, Horimoto Y et al. Ki67 heterogeneity in estrogen receptor-positive breast cancers: Which tumor type has the most heterogeneity? Int J Surg Pathol 24:103-7, 2016 Yamashita H, Horimoto Y et al. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 23:830-843, 2016 Sai S, Horimoto Y et al. Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro. Mol Cancer 14:166, 2015 Horimoto Y et al. Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients. J Clin Pathol 68:825-9, 2015 Horimoto Y et al. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases. Br J Cancer 112:345-51, 2015 Horimoto Y et al. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer 14:550, 2014 Shimizu H, Horimoto Y et al. Application of MammaPrint to Japanese breast cancer patients. Breast Care 10:118–122, 2015 Wang J, Horimoto Y et al. Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma. Cytokine 68:94-100, 2014 Karasawa K, Horimoto Y et al. Biological effectiveness of carbon-ion radiation on various human breast cancer cell lines. J Cell Sci Ther 2014, 5:5 Coombes R, Horimoto Y et al. An Open-Label Study of Lapatinib in Women with HER-2 Negative Early Breast Cancer: the Lapatinib Pre-Surgical Study. Ann Oncol 24:924-30, 2013 Ewington L, Horimoto Y et al. The Expression of Interleukin-8 and Interleukin-8 Receptors in Endometrial Carcinoma. Cytokine 59:417-422, 2012 Horimoto Y et al. ERbeta1 Represses FOXM1 Expression through Targeting ERalpha to Control Cell Proliferation in Breast Cancer. Am J Pathol 179:1148–1156, 2011 Millour J, Horimoto Y et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther 10:1046-1058, 2011 Horimoto Y et al. Significance of HER2 protein examination in ductal carcinoma in situ. J Surg Res 167:e205-210, 2011 Horimoto Y et al. Arthralgia in 329 patients taking aromatase inhibitors. Breast Care 4:319-323, 2009 |
| 研究者 | 教育活動 |